Ginkgo Bioworks Holdings Inc. (NYSE:DNA) remained unchanged to close Tuesday at $2.08 after subtracting $0.0 on the day. The 5-day average trading volume is 21,597,219 shares of the company’s common stock. It has gained $2.27 in the past week and touched a new high 1 time within the past 5 days. An average of 23,602,721 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 23,806,686.
DNA’s 1-month performance is 5.05% or $0.31 on its low of $1.75 reached on 07/10/23. The company’s shares have touched a 52-week low of $1.12 and high of $4.91, with the stock’s rally to the 52-week high happening on 07/19/23. YTD, DNA has achieved 23.08% or $0.39 and has reached a new high 9 times. However, the current price is down -57.64% from the 52-week high price.
Insider Transactions
DNA stock investors last saw insider trading activity on Aug 03.Kelly Jason R () most recently sold 100,000 shares at $2.04 per share on Aug 03. This transaction cost the insider $204,300. 10% Owner, Canton Barry, sold 37,650 shares at a price of $2.04 on Aug 03. Then, on Aug 03, Shetty Reshma P. sold 37,650 shares at a price of $2.04 per share. This transaction amounted to $76,919.
Valuation Metrics
DNA stock has a beta of 1.20. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 10.48 while the price-to-book (PB) in the most recent quarter is 2.48.
Ginkgo Bioworks Holdings Inc.’s quick ratio for the period ended March 30 was 6.90, with the current ratio over the same period at 6.90.. In terms of profitability, the gross margin trailing 12 months is 63.80%. The trailing 12-month EBITDA margin is -439.66%. The firm’s gross profit as reported stood at $273.49 million against revenue of $477.71 million.
Earnings Surprise
For the quarterly period ending March 30 this year, Net income and sales went down compared to those figures reported in the previous quarter. Analysts expected DNA to announce -$0.09 per share in earnings in its latest quarter, but it posted -$0.11, representing a -22.20% surprise. EBITDA for the quarter stood at more than -$196.79 million. DNA stock balance sheet for the quarter ending March 30 shows that total liabilities totaled 809.62 million, with total debt at $404.1 million. Shareholders hold equity totaling $1.97 billion.
Let’s look briefly at Ginkgo Bioworks Holdings Inc. (DNA) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 08 August was 44.30% to suggest the stock is trending Neutral, with historical volatility in this time period at 101.09%.
The stock’s 5-day moving average is $2.06, reflecting a -11.11% or -$0.26 change from its current price. DNA is currently trading +3.48% above its 20-day SMA, +56.39% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +35.95% and SMA200 by-14.75%.
Stochastic %K and %D was 21.21% and 15.76% and the average true range (ATR) pointed at 0.18. The RSI (14) points at 48.51%, while the 14-day stochastic is at 23.97% with the period’s ATR at 0.18. The stock’s 9-day MACD Oscillator is pointing at -0.13 and -0.19 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Ginkgo Bioworks Holdings Inc. (NYSE: DNA), Goldman downgraded it to a Sell rating. They previously had a Neutral rating on the stock. Analysts offering their rating for DNA stock have a consensus rating for the stock as Overweight. Currently, 1 brokerage advisors rate DNA as a “sell,”, while 2 advise that investors “Hold.” 1 analysts have rated the stock as underweight. 1 rates the stock as overweight while 4 have offered a “buy” rating.
What is DNA’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $1.25 and a high of $12.00, with their median price target at $3.20. Looking at these predictions, the average price target given by analysts is for Ginkgo Bioworks Holdings Inc. (DNA) stock is $4.24.
